hydrocortisone / Generic mfg. - LARVOL DELTA

OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov) - P3 | N=1314 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Suspended ➔ Active, not recruiting

Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

APHP191110: Rapid rEcognition of COrticosteroid Resistant or sentive Sepsis - RECORDS (clinicaltrialsregister.eu) - P2/3 | N=1800 | Completed | Sponsor: Assistance Publique Hopitaux De Paris | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Septic Shock • NFKB1

Prednisolone vs Hydrocortisone for Hypoadrenalism-An Uneven Battle. (PubMed, JAMA Netw Open) - No abstract available

Journal

CLINICAL RESPONSE, EFFICACY AND CHANGES OF IMMUNE FUNCTION WITH RITUXIMAB TREATMENT IN CHILDHOOD DIFFICULT NEPHROTIC SYNDROME (ISN-WCN 2026) - "SDNS patients with lack of steroid sparing effect (inability to sustain remission at a prednisone dose of 0.5 mg/kg every other day) or presence of significant steroid toxicity, despite treatment with oral cyclophosphamide (2 mg/kg per day for 12 weeks), levamisole (2.5 mg/kg for 6 months), mycophenolate mofetil (1200 mg/m2/day for 6 months), and calcineurin inhibitors (CNI) or those showing CNI induced nephrotoxicity were included...Premedication with oral acetaminophen (15 mg/kg), diphenhydramine (0.5 mg/ kg), intravenous hydrocortisone (4 mg/kg) was given 30 minutes before infusion of the RTX...Only one third of the cases developed B-cell depletion initially but typically recovered at 9-12 months of 1st dose of rituximab therapy. Serum IgG level was maintained but IgM level was reduced upto 12months."

Clinical • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease • Respiratory Diseases • CD20

ADJUNCTIVE HEMOADSORPTION WITH DNA 230 IN SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS WITH MULTIORGAN INVOLVEMENT: A CASE REPORT (ISN-WCN 2026) - "She exhibited SLE activity in renal, mucocutaneous, serosal, hematologic, and immunologic domains.She was started on ceftriaxone, paracetamol, N-acetylcysteine, hydrocortisone, calcium + vitamin D, losartan, and atorvastatin. She was discharged stable on day 25 on tapering corticosteroids with a scheduled renal biopsy.Renal, liver and inflammatory markersConclusion This case highlights the potential role of DNA 230 hemoadsorption as an adjunct to standard immunosuppression and dialysis in severe lupus with multiorgan involvement. By facilitating removal of cytokines and inflammatory mediators, hemoadsorption may accelerate recovery and improve organ function during lupus flares."

Case report • Clinical • Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Heart Failure • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases • Systemic Lupus Erythematosus

Acute kidney injury due to primary adrenal insufficiency: 2 case reports (ISN-WCN 2026) - "Four months later, his body weight had returned to baseline, eGFR had risen to 45 mL/min/1.73 m2, and blood pressure had improved.Case 2: A man in his 70s achieved complete remission of follicular lymphoma with obinutuzumab (OBZ) plus bendamustine and received maintenance OBZ...Prednisolone 30 mg/day plus hydrocortisone 5 mg/day were given for 7 days, followed by hydrocortisone 20 mg/day...Although both patients had hypotension, such modest hypotension alone is unlikely to cause marked renal dysfunction. In both cases, the kidney function decline was relatively slow—atypical for simple dehydration or uncomplicated AKI—suggesting mixed acute-on-chronic prerenal factors.As the use of immune checkpoint inhibitors increases, the incidence of PAI as an immune-related adverse event is rising, and it will become increasingly important to consider PAI as a potential cause of AKI.Conclusion When encountering a case of AKI with no apparent cause, PAI should be considered in the..."

Case report • Clinical • Acute Kidney Injury • Anorexia • Endocrine Disorders • Follicular Lymphoma • Glomerulonephritis • Hematological Malignancies • Hypotension • Lupus Nephritis • Lymphoma • Nephrology • Renal Disease

Prednisolone Once Daily vs Hydrocortisone Thrice Daily in Hypoadrenalism: A Randomized Clinical Trial. (PubMed, JAMA Netw Open) - P3 | "Studies assessing longer-term mortality and morbidity outcomes are needed. ClinicalTrials.gov Identifier: NCT03936517."

Clinical • Journal • Endocrine Disorders • Nephrology • Rare Diseases • Renal Disease

Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery. (PubMed, Clin Endocrinol (Oxf)) - "ICI-Hp is common and potentially associated with serious complications in the absence of prompt recognition and treatment. Assessment of recovery of the HP-thyroid and HP-gonadal axes is important; however, ACTH deficiency is more likely to be permanent, hence requiring long-term GC replacement and appropriate patient education. Occurrence of ICI-Hp is most commonly seen after the 3rd cycle of combination ICI therapy, and in the future it may be appropriate to warn treating physicians (and perhaps patients) of the symptoms to flag after the third cycle of combination immunotherapy."

Checkpoint inhibition • Journal • CNS Disorders • Diabetes • Endocrine Disorders • Fatigue • Melanoma • Metabolic Disorders • Nephrology • Oncology • Pain • Psychiatry • Renal Disease • Solid Tumor • Type 1 Diabetes Mellitus

Corticosteroids for Treating Sepsis: A Systematic Review and Network Meta-analysis. (PubMed, Respir Med) - "Notably, the mortality benefit of H 100 mg/d is preliminary due to limited evidence from a single small RCT. Corticosteroids reduce sepsis patients' short/long-term mortality and organ support duration, but no "optimal" dosage consensus exists. Further research is needed to refine dosage and personalize therapy."

Journal • Retrospective data • Infectious Disease • Septic Shock

Propylthiouracil Induced Neutropenia in Thyroid Storm: A Case Requiring Urgent Total Thyroidectomy. (PubMed, Int Med Case Rep J) - "Bridging therapy with hydrocortisone, cholestyramine, Lugol's solution, was implemented once available, and low-dose carbimazole was cautiously reintroduced under close monitoring without recurrence of neutropenia. Once a euthyroid state was achieved, definitive management with a total thyroidectomy was performed without complications. This case highlights three key learning points: (1) agranulocytosis can occur very early during high-dose PTU therapy; (2) careful bridging strategies are essential to prevent rebound thyroid storm after antithyroid drug withdrawal; and (3) timely transition to definitive surgical management can be lifesaving when antithyroid drug intolerance occurs."

Journal • Agranulocytosis • Endocrine Disorders • Granulocytopenia • Grave’s Disease • Hematological Disorders • Neutropenia

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed

Trial completion • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

The Effect of Dupilumab on Atopic Dermatitis–Related Emergency Department Visits: A Real-World Analysis (AAD 2026) - "Patients with AD were identified via validated ICD-10 codes and stratified into two cohorts: those treated with dupilumab and those treated with topical corticosteroids such as hydrocortisone, triamcinolone, and clobetasol but without dupilumab. Dupilumab therapy was associated with reduced risk of AD-related ED visits in a large, real-world dataset. These findings highlight the potential of biologic therapy to decrease acute care burden and support its broader role in comprehensive AD management."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis • Vitiligo

An Exploration of Perioral Dermatitis Triggers in a Cohort of 262 Patients (AAD 2026) - "“Other” triggers, which primarily consisted of over-the-counter hydrocortisone, were the most common self-reported triggers (11.1%; 95%CI: 7.8%-15.5%), followed by facial masking (10.7%; 95%CI: 7.5%-15.1%)... Corticosteroids were the most frequently identified POD trigger, supporting their avoidance in individuals with propensity for developing POD. Triggers were under-reported overall, highlighting gaps in clinical practice regarding trigger identification and avoidance. Future study is required to elucidate potential POD triggers."

Clinical • Dermatitis • Dermatology • Immunology

Dowling-Degos Disease Presenting as an Isolated Perianal Reticulated Patch (AAD 2026) - "Therapies to be considered for this case include adapalene or hydrocortisone. This case illustrates an unusual presentation of DDD localized to the perianal region. The lesion's location and reticulated morphology closely resembled other potentially serious pigmentary disorders, and this overlap underscores the importance of clinicopathologic correlation to establish the correct diagnosis."

Genito-urinary Cancer • Non-melanoma Skin Cancer • Prostate Cancer • Pruritus • Rare Diseases • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Vulvar Elastosis Mimicking Lichen Sclerosus: Two Cases with Management Implications (AAD 2026) - "Management changed accordingly: Patient 1 improved with a clobetasol taper plus estrogen therapy; Patient 2 transitioned to low-potency hydrocortisone with counseling. Vulvar elastosis is an important LS mimic in symptomatic postmenopausal patients. When H&E is equivocal, order an elastic stain. Correct identification prevents unnecessary long-term ultrapotent corticosteroids and LS surveillance and supports symptom-directed vulvar care."

Clinical • Dermatology • Pruritus • Solid Tumor

Association Between Cortisol Levels and Hemodynamic Illness Severity in Neonates With Catecholamine-Resistant Shock Treated With Hydrocortisone (PAS 2026) - No abstract available

Cardiovascular

Use of Hydrocortisone (HC): A Retrospective Look at Relative Adrenal Insufficiency (RAI) of Prematurity (PAS 2026) - No abstract available

Prematurity • Retrospective data • Endocrine Disorders • Nephrology • Renal Disease

Cumulative Hydrocortisone Exposure and Early Brain Volumetrics in Very Low Birth Weight Infants: Associations with Neurodevelopmental outcomes (PAS 2026) - No abstract available

Neurodevelopmental

Late hydrocortisone for bronchopulmonary dysplasia in preterm infants exposed to histological chorioamnionitis (PAS 2026) - No abstract available

Prematurity • Bronchopulmonary Dysplasia • Pulmonary Disease • Respiratory Diseases

PTSD Prevention Using Oral Hydrocortisone (clinicaltrials.gov) - P2 | N=201 | Completed | Sponsor: Rachel Yehuda | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) (clinicaltrials.gov) - P4 | N=2000 | Recruiting | Sponsor: Copenhagen Respiratory Research | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2026 ➔ Nov 2030 | Trial primary completion date: Aug 2026 ➔ Aug 2030

Enrollment open • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP) (clinicaltrials.gov) - P4 | N=1600 | Recruiting | Sponsor: Copenhagen Respiratory Research | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2026 ➔ Nov 2030 | Trial primary completion date: Aug 2026 ➔ Aug 2030

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Pneumonia • Respiratory Diseases

When Immunotherapy Meets COVID-19: A Perfect Storm for Adrenal Crisis (SCCM 2026) - "Introduction: Pembrolizumab, a PD-1 immune checkpoint inhibitor (ICI) used in immunotherapy, can cause rare but fatal immune-related adverse events such as adrenal insufficiency...High-dose intravenous hydrocortisone administration resulted in fast recovery of blood pressure together with sodium levels...The prompt administration of corticosteroids along with early diagnosis remains essential for preventing serious consequences. Artificial intelligence was utilized to support the drafting of the abstract in the preparation of this case report."

Cardiovascular • Endocrine Disorders • Heart Failure • Hematological Disorders • Hypotension • Immunology • Infectious Disease • Melanoma • Nephrology • Novel Coronavirus Disease • Pneumonia • Renal Disease • Respiratory Diseases • Solid Tumor

LIFE-THREATENING MULTI-SYSTEM IMMUNE CARDIOTOXICITY FOLLOWING PEMBROLIZUMAB: MYOCARDITIS WITH COMPLETE HEART BLOCK AND ENDOCRINE COLLAPSE (ACC 2026) - "Case: A 76-year-old man with metastatic lung adenocarcinoma (pembrolizumab cycle 8) presented with syncope due to CHB with a wide QRS ventricular escape rhythm (Figure A-B), requiring transcutaneous pacing (Figure C) and epinephrine...Hormone replacement with IV hydrocortisone and levothyroxine was initiated, achieving rapid hemodynamic stabilization... This case represents a fulminant irAEs requiring immediate recognition. The dramatic response to coordinated intervention highlights the critical need for heightened cardiovascular and endocrine surveillance in ICI-treated patients."

Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Hypotension • Inflammation • Lung Adenocarcinoma • Lung Cancer • Nephrology • Non Small Cell Lung Cancer • Renal Disease • Solid Tumor

Immune Checkpoint Inhibitor-Induced Hypophysitis: A Case Report (SCCM 2026) - "Introduction: Pembrolizumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) are immune checkpoint inhibitors (ICIs) that enhance immune-mediated tumor clearance...Diagnosis relies on hormonal assays; MRI may show pituitary enlargement but is sometimes normal.Glucocorticoid replacement is first-line, typically with stress-dose hydrocortisone...Most patients require lifelong hormone replacement.As ICIs become more common, intensivists must stay vigilant for endocrine irAEs. Prompt recognition and hormone replacement are essential to prevent ICU-level morbidity."

Case report • Checkpoint inhibition • Clinical • IO biomarker • Acute Kidney Injury • Cardiovascular • Endocrine Disorders • Heart Failure • Hypotension • Melanoma • Nephrology • Oncology • Renal Disease • Solid Tumor